Schizophrenia News and Research

Latest Schizophrenia News and Research

Considering varying extent to which genes are turned on or off can help develop personalised, predictive medicines

The vast majority of genetic disorders (schizophrenia or breast cancer, for example) have different effects in different people. Moreover, an individual carrying certain mutations can develop a disease, whereas another one with the same mutations may not. This holds true even when comparing two identical twins who have identical genomes. But why does the same mutation have different effects in different individuals?

8 Dec 2011

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

BioLineRx announced today the final results of the Phase Ia study of BL-1021, an orally available small molecule for neuropathic pain.

6 Dec 2011

Bold move by Astra Zeneca to share 22 early stage potential drugs with MRC

Drug maker AstraZeneca will be sharing 22 of its early-stage research compounds with the Medical Research Council as part of a make over of life sciences research. This would speed up patients’ access to breakthrough drugs and arrest the decline of research and development in the UK.

6 Dec 2011

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, announced today that it is presenting the comprehensive analysis of a recently completed Phase 2b clinical trial of EVP-6124, a novel, orally bioavailable nicotinic alpha-7 agonist, in schizophrenia at the American College of Neuropsychopharmacology 50th Anniversary Annual Meeting.

5 Dec 2011

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced the initiation of two clinical studies of TC-5619, a Phase 2b study evaluating the product candidate as a treatment for negative symptoms and cognitive dysfunction in schizophrenia and a Phase 2 study evaluating the product candidate in adults as a treatment for attention deficit/hyperactivity disorder (ADHD), inattentive-predominant.

5 Dec 2011

Study shows new biochemical disturbances in the brains of children with ADHD

A new study at örebro University in Sweden shows that children with ADHD have nearly 50 percent less of a protein that is important for attention and learning. The finding may mean that there are other biochemical disturbances in the brains of individuals with ADHD than was previously believed.

5 Dec 2011

Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting

Post-baseline vision data from Lundbeck's Sabril patient registry is available for the first time today as a late-breaking poster presentation at the annual meeting of the American Epilepsy Society.

5 Dec 2011

Government inspectors to lawmakers: More must be done to stop prescription of powerful psych drugs to nursing home patients

Government inspectors told lawmakers Wednesday that Medicare officials need to do more to stop doctors from prescribing powerful psychiatric drugs to nursing home patients with dementia, an unapproved practice that has flourished despite repeated government warnings.

1 Dec 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

Study looks at effects of antipsychotic drugs on two brain receptors linked to schizophrenia

Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.

24 Nov 2011

Neuralstem initiates spinal cord neural stem cell trial in ALS

Neuralstem, Inc. announced that the first patient to receive stem cells in the cervical (upper back) region of the spine was treated on Friday in its ongoing trial to test the safety of its spinal cord neural stem cells in amyotrophic lateral sclerosis.

23 Nov 2011

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.

22 Nov 2011

Scientists show that the sense of smell can be improved

In a new study scientists at NYU Langone Medical Center have shown that the sense of smell can be improved. The new findings, published online November 20, 2011, in Nature Neuroscience, suggest possible ways to reverse the loss of smell due to aging or disease.

20 Nov 2011

Senator Klein opens new Cognitive Neurophysiology Laboratory at Albert Einstein College of Medicine

New York State Senator Jeffrey D. Klein joined administrators and faculty members of Albert Einstein College of Medicine of Yeshiva University last Friday to officially open their new Cognitive Neurophysiology Laboratory.

19 Nov 2011

Study demonstrates how DISC1 variants affect brain development

Significant progress has been made in understanding the genetic risk factors underlying psychiatric disease. Recent studies have identified common genetic mutations conferring modest risk and rare variants comprising significant risk. One example of a rare cause of psychiatric disorders is the Disrupted in Schizophrenia-1 (DISC1) gene, first identified in a large Scottish pedigree displaying schizophrenia, bipolar disorder and depression.

18 Nov 2011

Psychiatric medication use soaring among women: Report

Attention Deficit Hyperactivity Disorder or ADHD commonly affects boys more than girls. However a new report shows that among adults, the numbers have changed with women’s use of ADHD medications risen over the past decade surpassing that of men.

17 Nov 2011

Researchers discover a factor in synapse-building and pruning

Like a gardener who stakes some plants and weeds out others, the brain is constantly building networks of synapses, while pruning out redundant or unneeded synapses. Researchers at The Jackson Laboratory led by Assistant Professor Zhong-wei Zhang, Ph.D., have discovered a factor in synapse-building, also showing that the building and pruning processes occur independent of each other.

17 Nov 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

Considering varying extent to which genes are turned on or off can help develop personalised, predictive medicines

Positive final results from BioLineRx BL-1021 Phase Ia study for neuropathic pain

Bold move by Astra Zeneca to share 22 early stage potential drugs with MRC

EnVivo presents positive EVP-6124 Phase 2b trial data on schizophrenia at 50th ACNP meeting

Targacept commences two clinical studies of TC-5619 for schizophrenia and ADHD

Study shows new biochemical disturbances in the brains of children with ADHD

Post-baseline vision data from Lundbeck's Sabril patient registry presented at AES meeting

Government inspectors to lawmakers: More must be done to stop prescription of powerful psych drugs to nursing home patients

BioLineRx reports third quarter net loss of NIS 7.9 million

Study looks at effects of antipsychotic drugs on two brain receptors linked to schizophrenia

Neuralstem initiates spinal cord neural stem cell trial in ALS

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

Scientists show that the sense of smell can be improved

Senator Klein opens new Cognitive Neurophysiology Laboratory at Albert Einstein College of Medicine

Study demonstrates how DISC1 variants affect brain development

Psychiatric medication use soaring among women: Report

Researchers discover a factor in synapse-building and pruning

New research identifies brain chemicals and circuits involved in mental illnesses

Combination of antipsychotic and antidepressant drugs may increase risk of CV mortality

N.Y. State Senator opens Einstein's new Cognitive Neurophysiology Lab

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Schizophrenia News and Research

Latest Schizophrenia News and Research

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Newsletters you may be interested in